Table 1 Demographic and clinical characteristics of the 37 patients with nongestational choriocarcinoma

Age at diagnosis, median (range), years

22 (9–44)

 < 15 years old

9 (24.3%)

 16–20 years old

9 (24.3%)

 21–25 years old

5 (13.5%)

 25–30 years old

5 (13.5%)

 > 30 years old

9 (24.3%)

Duration of follow-up, median (range), months

41 (1–269)

Primary location

 Ovary

34 (91.9%)

  Left

11 (32.3%)

  Right

22 (64.7%)

  Bilateral

1 (2.9%)

 Pituitary

2 (5.4%)

 Stomach

1 (2.7%)

Metastatic lesion

 Lung

15 (40.5%)

 Brain

2 (5.4%)

 Liver

2 (5.4%)

 Extensive pelvic metastases

4 (10.8%)

 Extensive abdominal metastases

4 (10.8%)

Initial symptoms

 Abdominal pain

24 (64.8%)

  Acute abdomen

6 (25.0%)

 Abnormal uterine bleeding

16 (43.2%)

 Insipidus

2 (5.4%)

 Pregnancy symptoms

3 (8.1%)

 Palpable abdominal mass

2 (5.4%)

 Hemoptysis

1 (2.7%)

 Cough

1 (2.7%)

 Fever

1 (2.7%)

 Headache

1 (2.7%)

 Melena

1 (2.7%)

Laboratory tests

 Serumβ-hcg, median (range), mIU/ml

15,126.7 (89.1–386,274)

 AFP, elevated

1/13 (7.7%)

Staging of ovarian NGC patients

 Ovarian cancer staging^a

N = 34

  I

14 (41.2%)

  II

2 (5.9%)

  III

2 (5.9%)

  IV

16 (47.1%)

 Choriocarcinoma staging^b

N = 34

  II

14 (41.2%)

  III

11 (32.4%)

  IV

9 (26.5%)